The response to re-emergence of yellow fever in Nigeria, 2017.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 25 02 2019
revised: 23 12 2019
accepted: 24 12 2019
pubmed: 15 1 2020
medline: 19 3 2020
entrez: 15 1 2020
Statut: ppublish

Résumé

Yellow fever (YF) is an acute viral hemorrhagic disease caused by the YF virus (arbovirus) which continues to cause severe morbidity and mortality in Africa. A case of YF was confirmed in Nigeria on the 12th of September 2017, 21 years after the last confirmed case. The patient belongs to a nomadic population with a history of low YF vaccination uptake, in the Ifelodun Local Government Area (LGA) of Kwara State, Nigeria. An active case search in Ifelodun and its five contiguous LGAs led to the listing of 55 additional suspect cases of YF within the period of the outbreak investigation between September 18 to October 6, 2017. The median age of cases was 15 years, and 54.4% were males. Of these, blood samples were collected from 30 cases; nine tested positive in laboratories in Nigeria and six were confirmed positive for YF by the WHO reference laboratory in the region; Institut Pasteur, Dakar. A rapid YF vaccination coverage assessment was carried out, resulting in a coverage of 46% in the LGAs, with 25% of cases able to produce their vaccination cards. All stages of the yellow fever vector, Aedes mosquito were identified in the area, with high larval indices (House and Breteau) observed. In response to the outbreak, YF surveillance was intensified across all States in Nigeria, as well as reactive vaccination and social mobilisation campaigns carried out in the affected LGAs in Kwara State. A state-wide YF preventive campaign was also initiated.

Identifiants

pubmed: 31935537
pii: S1201-9712(19)30507-7
doi: 10.1016/j.ijid.2019.12.034
pii:
doi:

Substances chimiques

Yellow Fever Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

189-196

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

William E Nwachukwu (WE)

Nigeria Centre for Disease Control, Nigeria. Electronic address: nwachukwu.william@ncdc.gov.ng.

H Yusuff (H)

Nigeria Field Epidemiology and Laboratory Training Programme, Nigeria.

U Nwangwu (U)

National Arbovirus and Vectors Research Centre, Enugu, Nigeria.

A Okon (A)

Nigeria Centre for Disease Control, Nigeria.

A Ogunniyi (A)

Nigeria Centre for Disease Control, Nigeria.

J Imuetinyan-Clement (J)

Nigeria Field Epidemiology and Laboratory Training Programme, Nigeria.

M Besong (M)

Nigeria Field Epidemiology and Laboratory Training Programme, Nigeria.

P Ayo-Ajayi (P)

Nigeria Field Epidemiology and Laboratory Training Programme, Nigeria.

J Nikau (J)

Nigeria Field Epidemiology and Laboratory Training Programme, Nigeria.

A Baba (A)

Nigeria Field Epidemiology and Laboratory Training Programme, Nigeria.

F Dogunro (F)

National Arbovirus and Vectors Research Centre, Enugu, Nigeria.

B Akintunde (B)

Nigeria Field Epidemiology and Laboratory Training Programme, Nigeria.

M Oguntoye (M)

Ministry of Health, Ilorin, Kwara, Nigeria.

K Kamaldeen (K)

Ministry of Health, Ilorin, Kwara, Nigeria.

O Fakayode (O)

Ministry of Health, Ilorin, Kwara, Nigeria.

O Oyebanji (O)

Nigeria Centre for Disease Control, Nigeria.

O Emelife (O)

National Primary Health Care Development Agency, Nigeria.

J Oteri (J)

National Primary Health Care Development Agency, Nigeria.

O Aruna (O)

Public Health England, United Kingdom.

E Ilori (E)

Nigeria Centre for Disease Control, Nigeria.

O Ojo (O)

Nigeria Centre for Disease Control, Nigeria.

N Mba (N)

Nigeria Centre for Disease Control, Nigeria.

P Nguku (P)

Nigeria Field Epidemiology and Laboratory Training Programme, Nigeria.

C Ihekweazu (C)

Nigeria Centre for Disease Control, Nigeria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH